EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Biomarkers That Predict Crohn’s Disease Outcomes

Pablo A Olivera iD, Mark S Silverberg

Journal of the Canadian Association of Gastroenterology · 02.02.2024 · 7 (1) · 59-67

DOI: 10.1093/jcag/gwad024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 02.09.2023. Verfasst von Pablo A Olivera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Crohn’s disease (CD), a chronic inflammatory condition of the digestive tract, poses significant challenges in terms of disease prognosis and treatment selection. Biomarkers have the potential to predict CD outcomes and guide clinical decision-making. This review aims to summarize the current literature on promising biomarkers associated with CD outcomes and their potential clinical implications. The identification of reliable biomarkers for CD outcomes is of paramount importance in tailoring treatment strategies, monitoring disease activity, and predicting the risk of complications. Clinical prognostic factors traditionally used to assess disease severity, and the likelihood of complications have limitations in accuracy and predictive value. Thus, there is a need for more precise biomarkers, particularly in newly diagnosed and treatment-naive patients. Pharmacogenomic markers, such as TPMT and NUDT15 polymorphisms, have been utilized to identify patients at risk of adverse events with thiopurine therapy. Several biomarkers, including HLA haplotypes, oncostatin M expression, and transcriptomic profiles, have shown associations with response to anti-TNF therapy. Confocal laser endomicroscopy and single-cell analyses hold promise in predicting treatment response to specific therapies. The identification of biomarkers associated with post-operative recurrence in CD is crucial, as it could lead to changes in management algorithms. Several promising microbiome signatures and proteomic profiles have been identified. In conclusion, biomarkers have the potential to revolutionize the management of CD by providing valuable prognostic information and guiding treatment decisions. However, further research and validation are necessary to establish their clinical utility and integration into routine practice.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasebiomarkersprecision medicineprediction

Autor:innen und Institutionen

  • Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Division of Gastroenterology and Hepatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Pablo A Olivera

Zitieren

APA

Olivera, P. A., & Silverberg, M. S. (2024). Biomarkers That Predict Crohn’s Disease Outcomes. Journal of the Canadian Association of Gastroenterology, 7(1), 59-67. https://doi.org/10.1093/jcag/gwad024

Vancouver

Olivera PA, Silverberg MS. Biomarkers That Predict Crohn’s Disease Outcomes. Journal of the Canadian Association of Gastroenterology. 2024;7(1):59-67. doi:10.1093/jcag/gwad024

BibTeX
@article{Olivera2024,
  author = {Olivera, Pablo A and Silverberg, Mark S},
  title = {Biomarkers That Predict Crohn’s Disease Outcomes},
  journal = {Journal of the Canadian Association of Gastroenterology},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {59--67},
  doi = {10.1093/jcag/gwad024}
}
Kostenlos starten →